Key facts
- Aflo Analytics’s last known valuation is $2.5M (Jan 2021).
- It has raised $430K; the latest was Later Stage VC in Mar 2025.
- Notable investors include Innovate UK, Techstart Ventures, Clarendon Fund Managers, Invest Northern Ireland, Duncreggan Student Village — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Aflo Analytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aflo Analytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aflo Analytics
Developer of a healthcare technology designed to provide information related to how to inhale medicines correctly. The company's technology leverages AI, sensors, and hyper-personalized data to get the medication deep into the lungs and aggregate the inhalation data with air quality, enabling the medical community and patients to improve asthma, COPD, and cystic fibrosis outcomes, as well as viral data to help identify asthma attack triggers.
- Sector
- Healthcare
- HQ
- Londonderry, United Kingdom
- Founded
- 2019
- Employees
- 2
- Website
- afloanalytics.com/
- Ownership
- Privately Held (backing)
Aflo Analytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aflo Analytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aflo Analytics in its N-PORT filings yet. We sweep new filings monthly.